{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T17:39:16Z","timestamp":1793122756666,"version":"4.5.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2004,10,28]],"date-time":"2004-10-28T00:00:00Z","timestamp":1098921600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2004,10,28]],"date-time":"2004-10-28T00:00:00Z","timestamp":1098921600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2005,1,1]]},"DOI":"10.1038\/sj.leu.2403556","type":"journal-article","created":{"date-parts":[[2004,10,28]],"date-time":"2004-10-28T17:56:19Z","timestamp":1098986179000},"page":"39-43","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Anagrelide is effective in treating patients with hydroxyurea-resistant thrombocytosis in patients with chronic myeloid leukemia"],"prefix":"10.1038","volume":"19","author":[{"given":"R T","family":"Silver","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2004,10,28]]},"reference":[{"key":"BF2403556_CR1","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1097\/00001622-199202000-00009","volume":"4","author":"RT Silver","year":"1992","unstructured":"Silver RT . Chronic myeloid leukemia. Curr Opin Oncol 1992; 4: 66\u201372.","journal-title":"Curr Opin Oncol"},{"key":"BF2403556_CR2","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1016\/S0889-8588(03)00088-1","volume":"17","author":"RT Silver","year":"2003","unstructured":"Silver RT . Chronic myeloid leukemia. Hematol Oncol Clin North Am 2003; 17: 1159\u20131173.","journal-title":"Hematol Oncol Clin North Am"},{"key":"BF2403556_CR3","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1055\/s-2007-996125","volume":"23","author":"F Ravandi-Kashani","year":"1997","unstructured":"Ravandi-Kashani F, Schafer AI . Microvascular disturbances, thrombosis, and bleeding in thrombocythemia: current concepts and perspectives. Semin Thromb Hemost 1997; 23: 479\u2013488.","journal-title":"Semin Thromb Hemost"},{"key":"BF2403556_CR4","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1055\/s-2007-996121","volume":"23","author":"JJ Michiels","year":"1997","unstructured":"Michiels JJ . Erythromelalgia and vascular complications in polycythemia vera. Semin Thromb Hemost 1997; 23: 441\u2013454.","journal-title":"Semin Thromb Hemost"},{"key":"BF2403556_CR5","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1055\/s-2007-996109","volume":"23","author":"PJ van Genderen","year":"1997","unstructured":"van Genderen PJ, Michiels JJ . Erythromelalgia: a pathognomonic microvascular thrombotic complication in essential thrombocythemia and polycythemia vera. Semin Thromb Hemost 1997; 23: 357\u2013363.","journal-title":"Semin Thromb Hemost"},{"key":"BF2403556_CR6","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1016\/0277-5379(83)90091-3","volume":"19","author":"T Barbui","year":"1983","unstructured":"Barbui T, Cortelazzo S, Viero P, Bassan R, Dini E, Semeraro N . Thrombohaemorrhagic complications in 101 cases of myeloproliferative disorders: relationship to platelet number and function. Eur J Cancer Clin Oncol 1983; 19: 1593\u20131599.","journal-title":"Eur J Cancer Clin Oncol"},{"key":"BF2403556_CR7","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1002\/1097-0142(19900801)66:3<549::AID-CNCR2820660324>3.0.CO;2-6","volume":"66","author":"P Fenaux","year":"1990","unstructured":"Fenaux P, Simon M, Caulier MT, Lai JL, Goudemand J, Bauters F . Clinical course of essential thrombocythemia in 147 cases. Cancer 1990; 66: 549\u2013556.","journal-title":"Cancer"},{"key":"BF2403556_CR8","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1200\/JCO.1990.8.3.556","volume":"8","author":"S Cortelazzo","year":"1990","unstructured":"Cortelazzo S, Viero P, Finazzi G, D'Emilio A, Rodeghiero F, Barbui T . Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia. J Clin Oncol 1990; 8: 556\u2013562.","journal-title":"J Clin Oncol"},{"key":"BF2403556_CR9","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/BF01707281","volume":"63","author":"A Wehmeier","year":"1991","unstructured":"Wehmeier A, Daum I, Jamin H, Schneider W . Incidence and clinical risk factors for bleeding and thrombotic complications in myeloproliferative disorders. A retrospective analysis of 260 patients. Ann Hematol 1991; 63: 101\u2013106.","journal-title":"Ann Hematol"},{"key":"BF2403556_CR10","doi-asserted-by":"publisher","first-page":"2926","DOI":"10.1002\/1097-0142(19910601)67:11<2926::AID-CNCR2820671136>3.0.CO;2-3","volume":"67","author":"M Colombi","year":"1991","unstructured":"Colombi M, Radaelli F, Zocchi L, Maiolo AT . Thrombotic and hemorrhagic complications in essential thrombocythemia. A retrospective study of 103 patients. Cancer 1991; 67: 2926\u20132930.","journal-title":"Cancer"},{"key":"BF2403556_CR11","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1006\/bcmd.1998.0166","volume":"24","author":"OM Trapp","year":"1998","unstructured":"Trapp OM, Beykirch MK, Petrides PE . Anagrelide for treatment of patients with chronic myelogenous leukemia and a high platelet count. Blood Cells Mol Dis 1998; 24: 9\u201313.","journal-title":"Blood Cells Mol Dis"},{"key":"BF2403556_CR12","doi-asserted-by":"crossref","unstructured":"Anagrelide Study Group. Anagrelide, a therapy for thrombocythemic states: experience in 577 patients. Am J Med 1992; 92: 69\u201376.","DOI":"10.1016\/0002-9343(92)90017-6"},{"key":"BF2403556_CR13","doi-asserted-by":"publisher","first-page":"29","DOI":"10.7326\/0003-4819-128-1-199801010-00005","volume":"128","author":"PJ Best","year":"1998","unstructured":"Best PJ, Daoud MS, Pittelkow MR, Petitt RM . Hydroxyurea-induced leg ulceration in 14 patients. Ann Intern Med 1998; 128: 29\u201332.","journal-title":"Ann Intern Med"},{"issue":"Suppl 1","key":"BF2403556_CR14","doi-asserted-by":"publisher","first-page":"79","DOI":"10.3109\/10428199609074364","volume":"22","author":"PJ van Genderen","year":"1996","unstructured":"van Genderen PJ, Leenknegt H, Michiels JJ, Budde U . Acquired von Willebrand disease in myeloproliferative disorders. Leuk Lymphoma 1996; 22 (Suppl 1): 79\u201382.","journal-title":"Leuk Lymphoma"},{"key":"BF2403556_CR15","first-page":"70a","volume":"100","author":"SM Fruchtman","year":"2002","unstructured":"Fruchtman SM, Petitt RM, Gilbert HS, Fiddler G, Lyne A, Anagrelide Study Group. Anagrelide: Analysis of long term safety and leukemogenic potential in myeloproliferative diseases (MPDs). Blood 2002; 100: 70a (abstr.).","journal-title":"Blood"},{"key":"BF2403556_CR16","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/s00280-003-0651-7","volume":"52","author":"AM Tsimberidou","year":"2003","unstructured":"Tsimberidou AM, Colburn DE, Welch MA, Cortes JE, Verstovsek S, O'Brien SM et al. Anagrelide and imatinib mesylate combination therapy in patients with chronic myeloproliferative disorders. Cancer Chemother Pharmacol 2003; 52: 229\u2013234.","journal-title":"Cancer Chemother Pharmacol"},{"key":"BF2403556_CR17","first-page":"32a","volume":"102","author":"S Fruchtman","year":"2003","unstructured":"Fruchtman S, Pettit RM, Gilbert H . Anagrelide therapy significantly reduces disease related symptoms in patients with myeloproliferative disorders. Blood 2003; 102: 32a (abstr.).","journal-title":"Blood"},{"key":"BF2403556_CR18","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1056\/NEJMoa022457","volume":"348","author":"SG O'Brien","year":"2003","unstructured":"O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003; 348: 994\u20131004.","journal-title":"N Engl J Med"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/2403556.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/2403556","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/2403556.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T01:10:15Z","timestamp":1648775415000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/2403556"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,10,28]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2005,1,1]]}},"alternative-id":["BF2403556"],"URL":"https:\/\/doi.org\/10.1038\/sj.leu.2403556","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,10,28]]},"assertion":[{"value":"22 December 2003","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2004","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2004","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}